Rheumatology Advance Access published online on December 16, 2003
Rheumatology, doi:10.1093/rheumatology/keh070
Rheumatology © British Society for Rheumatology 2003; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Papers
1 Department of Medicine, The University of Western Ontario, Canada
* Corresponding author. E-mail: janet.pope{at}sjhc.london.on.ca.
Received 24 April 2003
; accepted 13 October 2003
Objective. Scoring poorly on the health assessment questionnaire (HAQ) has recently been shown to be a strong predictor of morbidity and mortality in rheumatoid arthritis (RA), while a good HAQ score is predictive of a better outcome. In patients presenting with early diffuse scleroderma prognosis is variable. Our goal was to determine possible baseline predictors of future good outcomes. Methods. We used the raw data from two randomized controlled trials (RCTs) in early diffuse scleroderma: methotrexate (Pope et al.) and d-penicillamine (Clements et al.). Subjects in the methotrexate trial were divided into the following groups: (1) those with at least 20% improvement in the primary outcome measurements [patient global assessment, physician global assessment, UCLA skin tethering score, modified Rodnan skin score (MRSS), DLCO as % predicted and HAQ disability] at 1 yr vs (2) the others. Baseline factors (including age, gender, skin scores, physician and patient global assessments, HAQ disability and pain scores, DLCO and physical parameters) were analysed to find baseline variables strongly correlated with later improvement. These variables were explored in the d-penicillamine trial to determine if (in a separate trial) they were still predictive of improved outcome at 1 and 2 yr. Adjusted models were used to find baseline predictors of good outcome. The median HAQ-DI was 1.3 (methotrexate) and 1.0 (d-penicillamine). Results. A baseline HAQ disability score of less than the median was predictive of at least a 20% improvement at 1 and 2 yr with odds ratios of 1.77 to 5.05, in four of the five outcome measurements (in both groups); with strongly significant P values for 3 of 5 outcomes (UCLA skin score, MRSS, patient global skin score; P<0.02) from the methotrexate study group. These three outcomes were strongly correlated with improvement (r between 0.25 and 0.35). Although data from the d-penicillamine trial were less convincing, in both trials the less than median HAQ-DI and HAQ pain scores showed a stronger association with improved outcome, more so than age, gender, skin score and baseline global assessment. Conclusion. A low baseline HAQ (defined as less than the median HAQ score) is predictive of improved outcome in diffuse scleroderma at 1 and 2 yr.
Key words: Early diffuse scleroderma, HAQ, Prognosis, Good outcome.
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma
2 UCLA School of Medicine, Los Angeles, California, USA
3 *The Scleroderma Trials Study Group: D. E. Furst, J. R. Siebold, W. K. Wong, N. Bellamy, M. Mayes, M. Baron, B. White, M. Ellman, F. Wigley, S. Carette, M. H. Weisman, C. D. Smith, W. Barr, I. M. Chalmers, L. W. Moreland, T. A. Medsger Jr, P. Hong, V. Steen, D. O'Hanlon, R. W. Martin, E. Kaminska, D. Collier, J. Markland, E. Lally, J. Sibley, J. Varga, L. Catoggio, S. Weiner, B. Andrews and M. Abeles
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Nagy, Z. Balint, H. Farkas, J. Radics, G. Kumanovics, T. Minier, C. Varju, and L. Czirjak Establishment and partial validation of a patient skin self-assessment questionnaire in systemic sclerosis Rheumatology, March 1, 2009; 48(3): 309 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Czirjak, Z. Nagy, M. Aringer, G. Riemekasten, M. Matucci-Cerinic, D. E Furst, and on behalf of EUSTAR The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis Ann Rheum Dis, July 1, 2007; 66(7): 966 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Johnson and P. Lee The HAQ disability index in scleroderma trials Rheumatology, September 1, 2004; 43(9): 1200 - 1201. [Full Text] [PDF]
|
|